Medicines: Oncology Portfolio and Pipeline
At AstraZeneca, we aim to revolutionise cancer care with our portfolio, our pipeline and our people. We follow the science, wherever it takes us, in pursuit of the best medicines. Through this relentless quest for innovation, we have created one of the most diverse portfolios and pipelines in the industry - encompassing molecules and modalities designed to preferentially kill cancer cells, at every stage of disease.
Key disease areas
We are striving to make cure a reality for the millions of people across the world living with cancer every day. Our focus is on some of the most hostile and hard-to-treat cancers including pancreatic cancer, certain blood cancers, and cancers within breast, lung, ovarian, and prostate. By understanding the complexities of these cancer types, we can truly achieve life-changing benefits for patients.
We are balancing our focus on our industry-leading pipeline with the active life-cycle management of our existing medicines; expanding indications and exploring novel treatment combinations, to deliver to those patients with the greatest unmet need. Patients are always front of mind in everything we do – from the treatment options we provide and the daily impact these treatments can have.
Explore our key disease areas
Our scientific platforms
At AstraZeneca, our advances across our six scientific platforms have helped to improve patient outcomes. Further developments in epigenetics and across cell, gene and combination therapy hold the promise of new possibilities.
Our Oncology medicines
Our medicines at AstraZeneca are approved in individual countries for specific uses, and the information we provide for patients is governed by local regulations. In some countries, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. However, please note that in some countries we are not permitted to provide very much, or sometimes any, information on our prescription medicines, so you should only obtain information from trustworthy sources, and always ask a healthcare professional for advice about medicines.
goserelin acetate implant
Our Oncology pipeline
At AstraZeneca our industry-leading pipeline includes investigational therapies in various stages of clinical development - from approved medicines to earlier-stage molecules in clinical trials.
Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III or have been submitted for regulatory approval and may include assets that are launched in one or more major markets (removed when launched in all applicable major markets).
Oncology (as of 29 April 2022)
Collaboration in Oncology
Despite huge advances in cancer care over recent decades, at AstraZeneca, we know there is still more to be achieved. We cannot do this alone; we know that outsmarting cancer requires a collective and collaborative approach. From drug discovery collaborations to commercial partnerships, we are sourcing new medicines, investing in the brightest minds and funding research across the globe, with a focus on maximising impact through shared knowledge and experience.
Explore our Oncology pillars
Veeva ID: Z4-40328
Date of preparation: November 2021